BLA 761451 · Astrazeneca Ab
Saphnelo
Anifrolumab-Fnia · Single-Use · Type I Interferon Receptor Antagonist
Last checked: Nov 20, 2026Latest source record: Apr 24, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2026
Apr 24, 2026
Approved uses
1
Original approval plus efficacy supplements
Registered trials
32
11 Phase 3, 14 recruiting
FAERS reports
1,921
1,057 serious, 81 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 25, 2026.
SAPHNELO is indicated for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE), who are receiving standard therapy. Limitations of Use The efficacy of SAPHNELO has not been evaluated in patients with severe active lupus nephritis or severe active central nervous system lupus. Use of SAPHNELO is not recommended in these situations. SAPHNELO is a type I interferon (IFN) receptor antagonist indicated for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE), who are receiving standard therapy. ( 1 ) Limitations of Use: The efficacy of SAPHNELO has not been evaluated in patients with severe active lupus nephritis or severe active central nervous system lupus. Use of SAPHNELO is not recommended in these situations. ( 1 )
Mechanism: Anifrolumab-fnia is a human IgG1κ monoclonal antibody that binds to subunit 1 of the type I interferon receptor (IFNAR) with high specificity and affinity. This binding inhibits type I IFN signaling, thereby blocking the biologic activity of type I IFNs. Anifrolumab-fnia also induces the internalization of IFNAR1, thereby reducing the levels of cell surface IFNAR1 available for receptor assembly. Blockade of receptor mediated type I IFN signaling inhibits IFN responsive gene expression as well as downstream inflammatory and immunological processes. Inhibition of type I IFN blocks plasma cell...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
2 products under this application
- SAPHNELO · ANIFROLUMAB-FNIA 120MG/0.8ML · INJECTION, · Prescription
- SAPHNELO · ANIFROLUMAB-FNIA 300MG/2ML (150MG/ML · VIAL, SINGLE-USE · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Anifrolumab" as an intervention, any sponsor and status, largest first.
- Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued TreatmentPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07691970 · 1,072 participants (planned) · Start Aug 31, 2026 · Primary completion Dec 30, 2032
Drug: Anifrolumab · For: Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus Erythematosus
Sites: Phoenix, Arizona; Irvine, California; Los Angeles, California · 166 sites in all
- A Study of the Efficacy and Safety of MEDI-546 in Systemic Lupus ErythematosusPivotal-lookingCompleted
MedImmune LLCAstraZeneca (AZN)
NCT01438489 · 626 participants · Start Jan 2012 · Primary completion Apr 2015
Drug: Anifrolumab 300 mg; Anifrolumab 1000 mg · For: Systemic Lupus Erythematosus
Sites: Birmingham, Alabama; La Jolla, California; La Palma, California · 79 sites in all
- Long Term Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus ErythematosusPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT02794285 · 559 participants · Start Jun 30, 2016 · Primary completion Dec 21, 2021
Drug: Anifrolumab; Placebo · For: Active Systemic Lupus Erythematosus
Sites: Birmingham, Alabama; El Cajon, California; Hemet, California · 175 sites in all
- Efficacy and Safety of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus ErythematosusPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT02446912 · 460 participants · Start Jun 9, 2015 · Primary completion Jul 17, 2018
Drug: Anifrolumab; Placebo · For: Active Systemic Lupus Erythematosus
Sites: Birmingham, Alabama; El Cajon, California; La Jolla, California · 145 sites in all
- A Study of Outcomes in Chinese Patients Treated With Anifrolumab Who Have Active Mod-severe Systemic Lupus ErythematosusPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07751848 · 417 participants (planned) · Start Aug 31, 2026 · Primary completion Aug 25, 2028
Drug: Anifrolumab · For: Lupus Erythematosus, Systemic
Sites: Beijing, China; Bengbu, China; Changchun, China · 74 sites in all
- Efficacy and Safety of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus ErythematosusPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT02446899 · 373 participants · Start Jul 9, 2015 · Primary completion Sep 27, 2018
Drug: Anifrolumab; Placebo · For: Active Systemic Lupus Erythematosus
Sites: Covina, California; Hemet, California; Los Angeles, California · 113 sites in all
- Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus ErythematosusPivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT04877691 · 367 participants · Start Jun 8, 2021 · Primary completion Aug 22, 2025
Drug: Medi-546; Placebo · For: Systemic Lupus Erythematosus
Sites: Birmingham, Alabama; Paradise Valley, Arizona; Phoenix, Arizona · 140 sites in all
- Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus NephritisPivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT05138133 · 363 participants · Start Feb 15, 2022 · Primary completion Feb 23, 2027
Drug: Anifrolumab; Placebo · For: Lupus Nephritis
Sites: Glendale, Arizona; La Palma, California; Los Angeles, California · 164 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- systemic lupus erythematosus168
- fatigue147
- arthralgia109
- headache98
- nausea88
- pain79
- rash78
- herpes zoster69
- drug ineffective67
- product dose omission issue62
- condition aggravated59
- dyspnoea55
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2021 | 23 |
| 2022 | 191 |
| 2023 | 383 |
| 2024 | 478 |
| 2025 | 465 |
| 2026 | 381 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Saphnelo (Anifrolumab-Fnia)
2024 spending
$13.5M
Beneficiaries
417
2,642 claims
Per beneficiary
$32,279
$2,530.92 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $390,473 |
| 2022 | $4,315,125 |
| 2023 | $8,818,021 |
| 2024 | $13,460,205 |
Part B: Saphnelo (Anifrolumab-Fnia) · HCPCS J0491
2024 spending
$64.6M
Beneficiaries
1,877
12,979 claims
Per beneficiary
$34,410
2024 ASP limit $17.23 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $15,474,476 |
| 2023 | $39,863,663 |
| 2024 | $64,586,680 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Trial of Anifrolumab in Active Systemic Lupus Erythematosus.
Morand EF, Furie R, Tanaka Y, et al. · N Engl J Med 2020 · Clinical Trial, Phase III, Multicenter Study
- Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: A Randomized, Phase 3 Study.
Manzi S, Bruce IN, Morand EF, et al. · Arthritis Rheumatol 2026 · Randomized Controlled Trial, Clinical Trial, Phase III
- Management of systemic lupus erythematosus: a systematic literature review informing the 2023 update of the EULAR recommendations.
Kostopoulou M, Mukhtyar CB, Bertsias G, et al. · Ann Rheum Dis 2024 · Systematic Review
- Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus.
Furie R, Khamashta M, Merrill JT, et al. · Arthritis Rheumatol 2017 · Clinical Trial, Phase II, Randomized Controlled Trial
- A Randomized, Placebo-Controlled Phase III Extension Trial of the Long-Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus.
Kalunian KC, Furie R, Morand EF, et al. · Arthritis Rheumatol 2023 · Randomized Controlled Trial, Clinical Trial, Phase III
- Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials.
Baker T, Sharifian H, Newcombe PJ, et al. · Ann Rheum Dis 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
Sponsor: AstraZeneca
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.